Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Wells Fargo is rolling out Google’s Agentspace AI across its workforce—from branch tellers to top executives. The bank says ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Revenue at the unit, which houses AMD’s all-important artificial intelligence chips that are viewed as central to the company’s future growth, rose 14% to $3.2 billion. Analysts had seen the figure at ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...